Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-7022-2244
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.80 million
Profitability
Miscellaneous
Employees137
OptionableOptionable
Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions
What is Ascendis Pharma A/S's stock symbol?
Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."
How were Ascendis Pharma A/S's earnings last quarter?
Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings data on Wednesday, November, 28th. The biotechnology company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.29. The biotechnology company earned $0.02 million during the quarter, compared to the consensus estimate of $0.16 million. Ascendis Pharma A/S had a negative net margin of 38,569.44% and a negative return on equity of 45.44%. View Ascendis Pharma A/S's Earnings History.
When is Ascendis Pharma A/S's next earnings date?
What price target have analysts set for ASND?
8 Wall Street analysts have issued 1-year target prices for Ascendis Pharma A/S's shares. Their forecasts range from $60.00 to $88.00. On average, they expect Ascendis Pharma A/S's stock price to reach $78.25 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.
What is the consensus analysts' recommendation for Ascendis Pharma A/S?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.
Has Ascendis Pharma A/S been receiving favorable news coverage?
Media coverage about ASND stock has been trending negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Ascendis Pharma A/S's key competitors?
Some companies that are related to Ascendis Pharma A/S include Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG) and Alkermes (ALKS).
Who are Ascendis Pharma A/S's key executives?
Ascendis Pharma A/S's management team includes the folowing people:
- Mr. Michael Wolff Jensen, Chairman, Sr. VP & Gen. Counsel (Age 47)
- Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 58)
- Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 44)
- Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 49)
- Dr. Harald Rau, Sr. VP & Chief Scientific Officer (Age 48)
When did Ascendis Pharma A/S IPO?
(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.
Who are Ascendis Pharma A/S's major shareholders?
Ascendis Pharma A/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Matisse Capital (0.02%).
Which major investors are selling Ascendis Pharma A/S stock?
ASND stock was sold by a variety of institutional investors in the last quarter, including Matisse Capital.
How do I buy shares of Ascendis Pharma A/S?
Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ascendis Pharma A/S's stock price today?
One share of ASND stock can currently be purchased for approximately $73.07.
How big of a company is Ascendis Pharma A/S?
Ascendis Pharma A/S has a market capitalization of $3.07 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma A/S employs 137 workers across the globe.
What is Ascendis Pharma A/S's official website?
How can I contact Ascendis Pharma A/S?
Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]
MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
